Clarity Pharmaceuticals Ltd (CU6) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has a cash flow conversion efficiency ratio of -0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-47.79 Million ≈ $-33.82 Million USD) by net assets (AU$232.81 Million ≈ $164.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Clarity Pharmaceuticals Ltd to measure how much of total assets are equity-financed.
Clarity Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Clarity Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Clarity Pharmaceuticals Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Clarity Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Merida Industry Co Ltd
TW:9914
|
-0.009x |
|
Shanghai Laiyifen Co Ltd
SHG:603777
|
0.040x |
|
Transcat Inc
NASDAQ:TRNS
|
0.041x |
|
Syarikat Takaful Malaysia Bhd
KLSE:6139
|
-0.206x |
|
Thanh Thanh Cong Tay Ninh JSC
VN:SBT
|
0.001x |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
|
0.027x |
|
Gerresheimer AG
F:GXI
|
0.042x |
|
JBG SMITH Properties
NYSE:JBGS
|
0.002x |
Annual Cash Flow Conversion Efficiency for Clarity Pharmaceuticals Ltd (2018–2025)
The table below shows the annual cash flow conversion efficiency of Clarity Pharmaceuticals Ltd from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Clarity Pharmaceuticals Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$90.23 Million ≈ $63.84 Million |
AU$-54.77 Million ≈ $-38.75 Million |
-0.607x | -105.38% |
| 2024-06-30 | AU$146.30 Million ≈ $103.51 Million |
AU$-43.24 Million ≈ $-30.59 Million |
-0.296x | +25.66% |
| 2023-06-30 | AU$69.18 Million ≈ $48.95 Million |
AU$-27.50 Million ≈ $-19.46 Million |
-0.398x | -175.41% |
| 2022-06-30 | AU$92.24 Million ≈ $65.26 Million |
AU$-13.31 Million ≈ $-9.42 Million |
-0.144x | +61.87% |
| 2021-06-30 | AU$20.28 Million ≈ $14.35 Million |
AU$-7.68 Million ≈ $-5.43 Million |
-0.379x | +54.78% |
| 2020-06-30 | AU$8.16 Million ≈ $5.77 Million |
AU$-6.83 Million ≈ $-4.83 Million |
-0.837x | -108.35% |
| 2019-06-30 | AU$9.23 Million ≈ $6.53 Million |
AU$-3.71 Million ≈ $-2.62 Million |
-0.402x | +48.30% |
| 2018-06-30 | AU$1.93 Million ≈ $1.37 Million |
AU$-1.50 Million ≈ $-1.06 Million |
-0.777x | -- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic ra… Read more